Answers are grounded in this paper and cite their sources.
Background. Japan’s high-cost medical benefit caps monthly out-of-pocket payment by income and lowers the cap from the fourth qualifying month. The August 2026 reform raised the monthly caps, kept the lower cap, and added an annual cap over a fixed August–July year. We estimated its effect on what breast cancer patients pay. Methods. We simulated 15 courses before and after the reform by income category, start date, and brand or generic pricing. The benchmark was the increase for a patient who reaches the monthly cap every month: three months’ rise in the cap, 4,500 to 51,330 yen (US$28–323) across five income categories. Results. Of 60 combinations of one-year course and income category, payment was unchanged in 16, mostly endocrine courses; rose by no more than the benchmark in 26, mostly surgery and chemotherapy courses; and rose or fell with the course start in 18. The increase exceeded the benchmark in 8 of the 60, 7 in the two highest categories and none in the two lowest, reaching 409,840 yen (US$2,578) against a benchmark of 51,330 yen (US$323). Decreases, up to 664,647 yen (US$4,180), came only from the annual cap, reached in 1,423,481 of 21,475,422 course-years. Generic or biosimilar substitution, though cheaper, raised the annual payment in 23.30% of 51,873 upper-middle-category pairs (median across start days). Conclusions. The reform adds little or nothing for endocrine treatment, surgery, and standard chemotherapy. For year-long high-cost courses, the effect depends on income and start month, and a cheaper drug can cost the patient more.
No takes yet. Share an insight, caveat, or question.
Hara et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: